Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Fludarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.89 |
| ▸ | CA5A | P35218 | 1/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine SCHEMBL6342036 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL28482317 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL4105 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL31010885 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL31010884 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL21465082 | 1.00 | NT5E (0.89) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL12018226 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL12019517 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL1981701 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A | |
| Fludarabine SCHEMBL6882489 | 0.94 | LMNA (1.00) | NT5ELMNAHIF1ACA5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119868554-A | Application of NAT10 as target spot in diagnosis and treatment of NAT10 high expression acute myelogenous leukemia | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-25 | — | — | CN | claimed |
| US-20260090997-A1 | Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods | UNIV EMORY (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4590279-A1 | LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS ENCODING THERAPEUTIC GENES AND USES IN MEDICAL METHODS | Emory University (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250205335-A1 | SYNTHETIC TUMOR-INFILTRATING LYMPHOCYTES (TILS) | Hangzhou Chengyuan Biotechnology Co., Ltd. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025111589-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG RESISTANCE IN CELLS | MEDICI THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-119868554-A | Application of NAT10 as target spot in diagnosis and treatment of NAT10 high expression acute myelogenous leukemia | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-25 | — | — | CN | disclosed |
| CN-119677842-A | Artificially synthesized tumor infiltrating lymphocytes | 科士华(南京)生物技术有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023174398-A9 | SYNTHETIC TUMOR-INFILTRATING LYMPHOCYTES (TILS) | Hangzhou Chengyuan Biotechnology Co., Ltd. (CN) | 2025-02-27 | — | — | WO | disclosed |
| EP-4493681-A1 | SYNTHETIC TUMOR-INFILTRATING LYMPHOCYTES (TILS) | Keshihua (Nanjing) Biotechnology Co., Ltd (CN) | 2025-01-22 | — | — | EP | disclosed |
| CN-118931967-A | Compositions and methods for immunotherapy | 亘喜生物科技（上海）有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-9074185-B2 | Adoptive cell therapy with young T cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140030806-A1 | ADOPTIVE CELL THERAPY WITH YOUNG T CELLS | HUMAN SERVICES (US) | 2014-01-30 | — | — | US | disclosed |
| US-8383099-B2 | Adoptive cell therapy with young T cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110052530-A1 | ADOPTIVE CELL THERAPY WITH YOUNG T CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2011-03-03 | — | — | US | disclosed |
| US-20050215498-A1 | Method for the protection of endothelial and epithclial cells during chemotherapy | KLINIKUM DER UNIVERSITAET REGENSBURG (DE) | 2005-09-29 | — | — | US | disclosed |
| EP-1509235-A1 | METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY | Klinikum der Universität Regensburg (DE) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101468-A1 | METHOD FOR THE PROTECTION OF ENDOTHELIAL AND EPITHELIAL CELLS DURING CHEMOTHERAPY | KLINIKUM DER UNIVERSITÄT REGENSBURG (DE) | 2003-12-11 | — | — | WO | disclosed |
| US-6043038-A | MEASURING ACTIVITY BY INCUBATING DNA TEMPLATE, PRIMASE, AND RIBONUCLEOTIDE TRIPHOSPHATES TO FORM NUCLEIC ACID WITH DNA-RNA HETEROHYBRID REGIONS, CONTACTING WITH RECOGNITION AGENT HAVING TAG, IMMOBILIZING BY TAG TO SOLID SUPPORT, DETECTING | TULARIK, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| WO-1999007371-A1 | TREATMENT OF PROSTATE CANCER | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998059044-A1 | HIGH-THROUGHPUT SCREENING ASSAYS FOR MODULATORS OF PRIMASE ACTIVITY | TULARIK INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090997-A1 | Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods | PLTP, PCYT1A, PHOSPHO1 | DPP4 4222/4885NT5E 262/4885LMNA 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.